CClinicalTrials.gg
Sign In
CompletedNCT03544151Updated Mar 24, 2020

Swan-Ganz CCOmbo V for Obtaining an Optimal Depth of Right Internal Jugular Venous Catheter

An observational study in Insertion Depth of Central Venous Catheter, sponsored by RenJi Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-03-24.

Sponsored by RenJi Hospital · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
105
Ages
18 Years and older
Sex
All
01

Study summary

The investigators will perform a study to create formula for the optimal insertion depth of right internal jugular vein catheter.

Read the detailed description

Patients scheduled for cardiac surgery were studied.Determine the optimal insertion depth of right internal jugular vein catheter using Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V).The investigators measure the distance between the insertion point and the junction between right atrium and superior vena cava using Swan-Ganz CCOmbo V.

02

Conditions studied

  • Insertion Depth of Central Venous Catheter
03

In context

Lead sponsor

RenJi Hospital is the lead sponsor of 535 studies on the registry; 244 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Patients scheduled for cardiac surgery were studied

Inclusion criteria

  • Adult patient over 18 years of age undergoing mitral valve or/and tricuspid valve
  • Surgery under general anesthesia, requiring Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V) insertion through the right internal jugular vein.

Exclusion criteria

Exclusion Criteria:

  • A change in the mediastinal structure from previous neck surgery,thoracic surgery or cardiac surgery
  • Extracardiac vascular anomaly
  • Anatomical abnormality in neck and thorax
  • Refusal to enrol
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
105 participants (actual)
Patient registry
No

Interventions

  • DeviceSwan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V)

    Swan-Ganz CCOmbo V insertion

06

What researchers measure

Primary outcomes

  1. The distance

    The distance between the insertion point and the junction between right atrium and superior vena cava

    Time frame: After insertion of the Swan-Ganz Continuous Cardiac Output Thermodilutioon Cather (Swan-Ganz CCOmbo V) and during operation

07

Study locations

1 site
  • Diansan Su
    Shanghai, Shanghai 200127, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03544151
Lead sponsor
RenJi Hospital
Responsible party
Sponsor
First posted
Jun 1, 2018
Start date
Jul 10, 2018
Primary completion
Nov 25, 2019
Completion
Dec 27, 2019
Last update
Mar 24, 2020

Study contacts

qi lu, Dr.
study director · Renji Hospital, School of Medicine, Shanghai Jiaotong University, Shanghai, China

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies from this sponsor

RenJi Hospital

Start the discussion